

## **ICPM 2018**

### **Workshop 7**

#### **Big Data in Medicines Development: Facts and Belief**

##### **Topics:**

- **Use of artificial intelligence**
- **Application of real world data**
- **Implications for healthcare**

##### **Chairs:**

- **Shimizu, Eiko (The University of Tokyo, Japan)**
- **Kesselring, Gustavo (IFAPP Academy, Brazil)**

##### **Panelists:**

- **Dreyer, Nancy (IQVIA, US)**
- **Sasaki, Masahiro (Office of Healthcare Policy, Japan)**
- **Koski, Greg (ACRES, US)**
- **Shigeru Nakagawa (IBM Watson Health, Japan)**
- **Yamamoto, Yuji (Minacare Co., Ltd, Japan)**

##### **Objectives**

**In the last decade the massive amount of health related data at internet (Big Data) derived from basic sciences, clinical studies,EMR, and scientific publications has turned the human knowledge dependent of technological analytics approaches in the decision process of diseases diagnosis & treatment, medicines development and better healthcare policies.**

**In this session we have invited world class speakers to present and critically review how Big Data and Artificial Intelligence will change the future landscape of medicines development and healthcare systems.**

## **Learning Outcomes**

**At the end of this session the attendees will be able to:**

- **Understand if machine learning and Artificial Intelligence can accelerate drug development to produce cheaper and more efficient medicines in the future**
- **Recognize how Artificial Intelligence can change the way doctors make more accurate and faster diagnosis and discuss if doctors will be replaced by machines in the future.**
- **Review the real advantages of Real world observational data in medicines development and its impact in the healthcare systems**
- **Learn what are the Japanese regulators plans in using Big Data and Artificial Intelligence for medicines development and to improve its healthcare system**